Advice

Which is a comprehensive test for mutation analysis of resistant imatinib patients in CML?

Which is a comprehensive test for mutation analysis of resistant imatinib patients in CML?

Focus Test Summary Detects over all 90 known as well as novel mutation in the ABL kinase domain (at codon 219-506) of Ph chromosome including T3151 & P- loop mutations responsible for resistance to Imatinib.

How long does it take to get BCR-ABL results?

BCR-ABL1 testing requires specialized equipment and expertise and your sample may be sent to a specialized hospital laboratory or a reference laboratory. It may take one to several days for your results to be available.

How common is T315I mutation?

The prevalence of the T315I mutation was found to be 7% (4/60). All four patients with mutation were in advance phases and had previously lost all their responses.

What is TKI treatment?

Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy. TKIs come as pills, taken orally. A targeted therapy identifies and attacks specific types of cancer cells while causing less damage to normal cells.

What is the most common mutation for CML?

This study showed 43% of patients having mutations and E255V/K was the most common mutation followed by Y253H/F. The importance of presence of these mutations in CML patients on imatinib without resistance has been studied by Branford S et al.

What is Irma test?

This test is useful for detecting over 90 known and novel mutations in ABL kinase domain of Ph chromosome including T3151 and P-loop mutations responsible for resistance to Imatinib in CML patients.

What does BCR gene do?

The BCR gene provides instructions for making a protein whose function is not completely understood. Studies show that the BCR protein may act as a GTPase activating protein (GAP). GAPs turn off (inactivate) proteins called GTPases, which play an important role in chemical signaling within cells.

What does p210 BCR-ABL1 mean?

Positive. BCR-ABL1 fusion transcripts (p210) detected. BCR-ABL1/ABL1 quantitative ratio is provided (normalized copy number) Weakly positive. BCR-ABL1 fusion transcripts detected below the limit of quantitation.